Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor developed by Merck.> In October 2006, Sitagliptin phosphate Januvia was appεroved by FDA as the first DPP4 inhibitor for the treatment of type ⅱ diabetes mellitus. The c£haracteristics of this drug are that it can stimulate insu♣lin secretion while reducing hunger without causing weight gain. Hypoglycemia and edema will not oc€cur, and it is suitable for diabetic patients with po¥or blood glucose control and frequent hypoglycemia.

key word:

hypoglycemia treatment stimulate

Category:

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to build a large health industry finance p¥latform company integrating pharmaceutical, intelligent medical, bio pharmaceu tical R&D, industrial production and sales.

The chemical reactions involved in the existing produc'ts include Foucault reaction, nitration reaction, sulfonation reaction, hydrogenat ion reaction, fluorination reaction, chlorination reaction, bromination reaction, diazo'tization reaction, format reaction, etc.

Blockbuster drug for type 2 diabetes

It is a dipeptidyl peptidase-4 (DPP4) inhibitor developed by Merck. In October 2006, ÷Sitagliptin phosphate Januvia was approved by FDA as the first DPP4 i&nhibitor for the treatment of type ⅱ diabetes mellitus. The characteristics of this ₩drug are that it can stimulate insulin secretion while red≤ucing hunger without causing weight gain. Hypoglyce•mia and edema will not occur, and it is suitable for diabetic patiσents with poor blood glucose control and frequent hypoglyce​mia. By inhibiting the activity of this enzyme, the drug can reδlatively increase the levels of naturally occurring increti‍n, including glucagon-like peptide-1 and glucose-dependent insulin-stimulating peptide, th∞ereby triggering the clinical effect of increasing insulin production in the pancreas a•nd stopping glucose production in the liver, ultimately lowering blood ‍glucose concentration. The DRUG HAS A PROMISING MARKET, WI≤TH SALES OF sitaglipTIN PHOSPHATE REACHING $185 MILLION IN THE THIRD quarter OF 2007 alone. P★eak sales of sitagliptin are forecast to reach $1 billion by 2010. $3.306 billion iσn 2020, combined with metformin in 2020 sales of $1.971 billion.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor developed by Mer®ck. In October 2006, Sitagliptin phosphate Januvia was approved by FDA ®as the first DPP4 inhibitor for the treatment of type ⅱ diabetes mellitus. The ↓characteristics of this drug are that it can stimulate insulin secretion while reducing hunge&r without causing weight gain. Hypoglycemia and edema will not occur, and it is suitable✘ for diabetic patients with poor blood glucose control and​ frequent hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-o"riented and realizes industrial development through R&D innovation and te‍chnology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one of the most impo>rtant products for the treatment of arthritis. It is weσll tolerated and has a low incidence of side effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major leukotrΩiene receptor antagonists. In clinical application, it has g∏ood therapeutic effect on atopic asthma and other types of bronchial asthma, ‍and the market prospect is huge. In the major category of asthma drugs, leuk§otriene receptor antagonists have the fastest growing market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise th↑at is market-oriented and realizes industrial development through R&D innovation and technology ≥transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the s<econd drug approved by FDA for Alzheimer's disease in the United States. Its treatment rea'ches the target dose and has low toxic and side eff®ects. It has been widely recognized by our medical community, and good tolerance is its bεiggest advantage. In October 1999, Donepezil was launch≈ed in China under the trade name "Aricept", which is the main chemical drug againπst Alzheimer's disease. At present, CFDA has approved a number of domestic ente₹rprises to produce donepezil preparations, the maiδn dosage forms are tablets, capsules, dispersive tablets, oral disintegrat¥ing tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bristol-Myers Sq'uibb/Pfizer), a direct oral factor Xa inhibitor, was approved for use in the 27 EU member statesα. The world's first drug approved to prevent venous thromboembolism (VTE) in adult patients under going elective hip or knee replacement. From June 2019 to June 2020, theφ annual sales of apixaban products overseas reached about $15.4 bil£lion, with a year-on-year growth of nearly 32%, and the API consumption reached about 23,960  kg, with a year-on-year growth of about 28%. Compared with its main competitor, Rivaroxa'ban, the drug's annual overseas sales are about $4.©5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech p×harmaceutical enterprise that is market-oriented and realizes industrial >development through R&D innovation and technology transformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactured by Genz÷yme. On December 29, 2004, it was approved by FDA for the treatment of refractory φor relapsed acute lymphoblastic leukemia (ALL) in childr∏en.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise thαat is market-oriented and realizes industrial development throughβ R&D innovation and technology transformation.

Product Consulting

Our staff will contact you within 24 hours (working days)∞. If you need other services, E-mail: 2880705932@qq.com